Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
80 studies found for:    "Valganciclovir"
Show Display Options
Rank Status Study
1 Completed Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition
Condition: Healthy
Intervention: Drug: Valganciclovir Hydrochloride
2 Completed Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition
Condition: Healthy
Intervention: Drug: Valganciclovir Hydrochloride
3 Not yet recruiting Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Condition: Congenital Cytomegalovirus (CMV)
Intervention: Drug: Valganciclovir
4 Completed
Has Results
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: Valganciclovir
5 Completed
Has Results
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Condition: Infection in Solid Organ Transplant Recipients
Intervention: Drug: prophylactic Valganciclovir
6 Completed
Has Results
Valganciclovir to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Placebo
7 Completed Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Condition: Cytomegalovirus Infection
Intervention: Drug: Single arm (ganciclovir and valganciclovir)
8 Withdrawn Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
Condition: Giant Lymph Node Hyperplasia
Intervention: Drug: Valganciclovir
9 Completed
Has Results
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Condition: Sarcoma
Intervention: Drug: valganciclovir
10 Terminated Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Condition: Allogeneic Stem Cell Transplantation
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
11 Completed
Has Results
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Condition: Kidney Transplantation, Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
12 Completed
Has Results
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Condition: Cytomegalovirus Infection
Interventions: Other: Placebo;   Drug: Valganciclovir
13 Completed Valganciclovir in Congenital CMV Infants
Condition: Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
14 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Transplantation Infection;   Epstein-Barr Virus Infections;   Cytomegalovirus Infections
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
15 Completed
Has Results
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Conditions: EBV Viremia;   CMV Viremia
Interventions: Drug: Valganciclovir;   Drug: Placebo
16 Completed
Has Results
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir;   Other: Placebo
17 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
18 Completed
Has Results
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
19 Not yet recruiting A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Valganciclovir;   Drug: Placebo
20 Terminated Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.